References
- Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003; 30 (1): 9–25.
- Pujol JL, Carestia, Daures JP. Is there a case for cis-platin in the treatment of small cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83 (1): 8–15.
- LeLorier J, Gregorie G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Eng J Mad 1997; 337 (8): 536–542.
- Bailar JC. The promise and problems of meta-analysis. N Eng J Med 1997; 337 (8): 559–561.
- World Health Organization: Handbook for reporting results of cancer treatment. Geneva: World Health Organization 1979.
- National Cancer Institute Common Toxicity Criteria. Version 2.0 January 30, 1998. http://ctep.info.nih.gov/CTC3/ctc.htm.
- Krug LM, Miller VA. Introduction: small cell lung cancer. A frustrating disease. Semin Oncol 2003; 30 (1): 1–2.
- Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for exten-sive small cell lung cancer. N Eng J Med 2002; 346: 85–91.
- Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow up. Lung Cancer 2003; 39 (3): 303–313.
- Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cis-platin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991; 83: 855–861.
- Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxoru-bicin and vincristine in limited small cell lung cancer. J Clin Oncol 1988; 6: 451–456.
- Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987; 107: 451–458.
- Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regi-mens in extensive small cell lung cancer: a phase III trial of the Southeastern cancer Study Group. J Clin Oncol 1992; 10: 282–291.
- Yuichi A, Figg W. Irinotecan in small cell lung cancer. N Eng J Med 2002; 346 (18): 1414–1415.